Skip to main content

Table 1 Patients’ demographic and clinical characteristics

From: Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?

 

Group A (SST)

n = 100

Group B (LST)

n = 100

p

Mean age (years)

52.4 ± 16.2

(range 18–89)

54 ± 15.3

(range 18–81)

0.458

Gender

 - Female

 - Male

55%

45%

60%

40%

0.567

Smoking habits

8%

8%

1

Alcohol consumption

19%

10%

0.107

Indication(s) for H. pylori eradication

 - Non-ulcer dyspepsia

 - Peptic ulcer

 - GERD/chronic use of PPI

 - Before bariatric surgery

 - Anemia or thrombocytopenia

 - Familial history of gastric cancer

63%

14%

11%

9%

2%

1%

72%

10%

11%

---

7%

---

0.307

0.452

1

---

0.229

---

Nitroimidazole antibiotic

 - Tinidazole

 - Metronidazole

53%

47%

81%

19%

0.001

Metronidazole dosage

 - 500 mg 12–12 h (1000 mg)

 - 500 mg 8–8 h (1500 mg)

29,8%

70,2%

21,1%

79,9%

0.554

PPI 1st or 2nd generation

 - Omeprazole / Pantoprazole / Lansoprazole

 - Esomeprazole / Rabeprazole

81%

19%

89%

11%

0.165

PPI dosage

 - Full-dose

 - Half-dose

91%

9%

88%

12%

0.645

Prescribing Physician

 - Gastroenterologist

 - Non-Gastroenterologist

79%

21%

94%

6%

0.002

  1. SST standard sequential treatment, LST levofloxacin-based sequential treatment, GERD gastroesophageal reflux disease, PPI proton-pump inhibitor